1. Home
  2. GLUE vs HDSN Comparison

GLUE vs HDSN Comparison

Compare GLUE & HDSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • HDSN
  • Stock Information
  • Founded
  • GLUE 2019
  • HDSN 1991
  • Country
  • GLUE United States
  • HDSN United States
  • Employees
  • GLUE N/A
  • HDSN N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • HDSN Industrial Specialties
  • Sector
  • GLUE Health Care
  • HDSN Consumer Discretionary
  • Exchange
  • GLUE Nasdaq
  • HDSN Nasdaq
  • Market Cap
  • GLUE 351.2M
  • HDSN 410.9M
  • IPO Year
  • GLUE 2021
  • HDSN 1994
  • Fundamental
  • Price
  • GLUE $4.80
  • HDSN $10.16
  • Analyst Decision
  • GLUE Buy
  • HDSN Buy
  • Analyst Count
  • GLUE 2
  • HDSN 4
  • Target Price
  • GLUE $13.50
  • HDSN $8.38
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • HDSN 429.8K
  • Earning Date
  • GLUE 08-07-2025
  • HDSN 07-30-2025
  • Dividend Yield
  • GLUE N/A
  • HDSN N/A
  • EPS Growth
  • GLUE N/A
  • HDSN N/A
  • EPS
  • GLUE 0.29
  • HDSN 0.40
  • Revenue
  • GLUE $177,986,000.00
  • HDSN $224,778,000.00
  • Revenue This Year
  • GLUE $83.76
  • HDSN $3.02
  • Revenue Next Year
  • GLUE N/A
  • HDSN $8.53
  • P/E Ratio
  • GLUE $16.32
  • HDSN $25.67
  • Revenue Growth
  • GLUE 2990.57
  • HDSN N/A
  • 52 Week Low
  • GLUE $3.50
  • HDSN $5.11
  • 52 Week High
  • GLUE $12.40
  • HDSN $10.34
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • HDSN 68.01
  • Support Level
  • GLUE $4.54
  • HDSN $9.32
  • Resistance Level
  • GLUE $4.93
  • HDSN $10.34
  • Average True Range (ATR)
  • GLUE 0.21
  • HDSN 0.24
  • MACD
  • GLUE 0.06
  • HDSN 0.01
  • Stochastic Oscillator
  • GLUE 81.43
  • HDSN 82.35

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About HDSN Hudson Technologies Inc.

Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.

Share on Social Networks: